Eli Lilly and Company’s Stock Price Dips to $1075.47, Marks a 2.61% Decline: Is it Time to Buy?

Eli Lilly and Company (LLY)

1075.47 USD -28.87 (-2.61%) Volume: 2.73M

Eli Lilly and Company’s stock price currently stands at 1075.47 USD, experiencing a slight dip of -2.61% in this trading session while maintaining a robust trading volume of 2.73M. Despite the day’s decline, the pharmaceutical giant’s stock remains strong with an impressive YTD gain of +43.05%.

Latest developments on Eli Lilly and Company

Eli Lilly & Co. has been making headlines recently, with JPMorgan analysts bullish on the stock and raising its price target to $1,150. The pharmaceutical giant became the first in its industry to reach a $1 trillion valuation, driven by strong demand for its obesity drug. Despite this milestone, some experts like Len Yaffee caution that it may be hard for Eli Lilly to see significant gains in the short term. The stock rose 30% in November but underperformed on Friday, prompting questions about a potential stock split. With investors closely watching Eli Lilly’s movements, it remains to be seen how the company will continue to navigate the market.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a positive long-term outlook. With a high score in Momentum, the company is showing strong growth potential and market performance. Additionally, Eli Lilly & scores well in Growth, indicating promising prospects for expansion and development in the future. While the Value score is not as high, the overall outlook for the company appears to be favorable, suggesting that investors may see good returns in the long run.

Eli Lilly & Company is a pharmaceutical company that focuses on discovering, developing, and selling products for both humans and animals. With a diverse range of products in areas such as neuroscience, endocrine, and oncology, the company has a solid foundation in the healthcare industry. The Smartkarma Smart Scores for Eli Lilly & show strengths in areas like Growth and Momentum, indicating a positive trajectory for the company’s future performance and market position.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma